| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 35.5 | 27.3 |
| Gross profit | 20.3 | 15.1 |
| Net income | -24.4 | -14.2 |
| EPS (diluted, $ a share) | $-0.52 | $-0.33 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +30.3% |
|---|---|
| Gross margin | 57.3% |
| Operating margin | -74.9% |
10-Q filed with the SEC, NASDAQ: BBNX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Beta Bionics, Inc.: key numbers
- Share price
- $15.21Close, Nov 16
- Market cap
- $827M
- Shares outstanding
- 54.37MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Beta Bionics, Inc.
All →Beta Bionics CFO Stephen Feider Sells $153K of Stock
Stephen Feider, CFO, sold 8,874 shares of Beta Bionics, Inc. at $17.21 a share, worth $153K in total on Nov 11, 2026. Shares held after the trade: 159,378 (-5.3%).
- Value
- $153K
- Shares
- 8,874
- Price
- $17.21
- Role
- CFO
- Holding change
- -5.3%
- Trade date
- Nov 11, 2026
Beta Bionics CFO Stephen Feider Sells $12.6K of Stock
Stephen Feider, CFO, sold 744 shares of Beta Bionics, Inc. at $17.00 a share, worth $12.6K in total on Nov 9, 2026. Shares held after the trade: 159,378 (-0.5%).
- Value
- $12.6K
- Shares
- 744
- Price
- $17.00
- Role
- CFO
- Holding change
- -0.5%
- Trade date
- Nov 9, 2026
Beta Bionics Chief Product Officer Mike Mensinger Sells $58.3K of Stock
Mike Mensinger, Chief Product Officer, sold 2,650 shares of Beta Bionics, Inc. at $22.00 a share, worth $58.3K in total on Oct 27, 2026. Shares held after the trade: 174,740 (-1.5%).
- Value
- $58.3K
- Shares
- 2,650
- Price
- $22.00
- Role
- Chief Product Officer
- Holding change
- -1.5%
- Trade date
- Oct 27, 2026
Beta Bionics Chief Commercial Officer Mark Hopman Sells $16.4K of Stock
Mark Hopman, Chief Commercial Officer, sold 821 shares of Beta Bionics, Inc. at $20.00 a share, worth $16.4K in total on Oct 26, 2026. Shares held after the trade: 54,513 (-1.5%).
- Value
- $16.4K
- Shares
- 821
- Price
- $20.00
- Role
- Chief Commercial Officer
- Holding change
- -1.5%
- Trade date
- Oct 26, 2026
Beta Bionics Financial Results
Beta Bionics reported Q3 2026 net sales of $35.5 million, a 30% increase year-over-year, driven by significant growth in its Pharmacy Benefit Plan channel. The company updated its full-year 2026 revenue guidance to $124-$126 million and announced plans to resubmit its 510(k) for the 3D Intelligence algorithm in mid-Q4 2026.
Beta Bionics Chief Commercial Officer Mark Hopman Sells $13.4K of Stock
Mark Hopman, Chief Commercial Officer, sold 775 shares of Beta Bionics, Inc. at $17.35 a share, worth $13.4K in total on Oct 14, 2026. Shares held after the trade: 55,334 (-1.4%).
- Value
- $13.4K
- Shares
- 775
- Price
- $17.35
- Role
- Chief Commercial Officer
- Holding change
- -1.4%
- Trade date
- Oct 14, 2026